Back to Directory
ACE-083
Performance & EnduranceLocalized muscle growth agent for specific muscle groups, under clinical investigation.
Key Benefits
- ✓Localized muscle growth
- ✓Increases specific muscle volume
- ✓For muscle-wasting diseases
- ✓Site-specific effects
Dosing Information
Dosage Range
Variable
Frequency
Clinical trial protocols
Typical Duration
Under investigation
Detailed Protocol
Administered via intramuscular injection directly into target muscle. In clinical trials for rare muscle diseases. Not available for general use.
About ACE-083
ACE-083 is a locally-acting muscle agent that inhibits signaling of select proteins in the TGF-beta superfamily. Unlike systemic myostatin inhibitors, it is designed for intramuscular injection to grow specific muscle groups. In clinical trials for muscular dystrophy.
Research Notes
Clinical trials ongoing for Charcot-Marie-Tooth and facioscapulohumeral muscular dystrophy. Shows localized muscle volume increases.
Potential Side Effects
- •Under clinical investigation
- •Muscle stiffness reported in trials
- •Limited data
Always consult with a healthcare professional before starting any peptide therapy.